Please refer to JobSuchmaschine in your application
Postdoctoral Researcher to lead biomarker project linked to clinical development of novel anti-cancer targeted therapy
Postdoctoral position in the UPRAD laboratory at the Swiss Institute for Experimental Cancer Research (ISREC).Prof. Freddy Radtke, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
The UPRAD laboratory is interested in the molecular mechanisms controlling stem cell maintenance, lineage commitment and differentiation in self-renewing systems with a strong focus on the NOTCH pathway, which is often deregulated during tumorigenesis. The general concept is that a better understanding of the mechanisms controlling stem maintenance versus differentiation may lead to the identification of novel therapeutic targets and therapeutic agents. Recently our laboratory has identified novel first-in-class inhibitors of the NOTCH pathway, leading to the creation of a start-up company, Cellestia Biotech AG. The most advanced development candidate, CB-103, has recently received regulatory approval to start Phase I clinical trial by Q4 2017.
In collaboration with Cellestia Biotech AG, a postdoctoral position is available in the laboratory of Prof. Freddy Radtke (EPFL, https://radtke-lab.epfl.ch/page-11024.html), to lead a CTI-sponsored project on the development and characterization of novel biomarkers for the NOTCH pathway.
The candidate must be a hands-on scientist with good communication skills, highly organized, passionate for bench work, translational research, ability to work in multidisciplinary environment, with a track record in characterizing antibodies using various techniques.
Required scientific skills:
Appointment is for 2-years, starting as soon as possible. Candidates should send a CV, brief statement of previous research, and email addresses and phone numbers of two references to:
Prof. Freddy Radtke
Office: SV 2534
Phone: +41 21 693 0771
Office: SV 2515
Phone: + 41 21 693 0772
SV ISREC UPRAD
Fax : +41 21 693 0745